CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 371 enrolled
Drug / intervention
0.5% Ivermectin Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01068158
NCT01068158Phase 3Completed

A Double-Blind Randomized Study to Compare the Efficacy, Safety, and Local Tolerability of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation

Topaz Pharmaceuticals Inc·interventional·Posted Feb 12, 2010·Updated Apr 6, 2012

In Brief

A Phase 3 clinical trial evaluating 0.5% Ivermectin Cream and Placebo control for Head Lice. Completed, enrolled 371 participants across 7 sites.

Detailed Summary

The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead Lice
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 12, 2010
Enrollment StartMar 1, 2010
Primary CompletionJun 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.4 years ago

Interventions

0.5% Ivermectin Creamdrug

Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.

Placebo controldrug

up to 4 ounces of topical vehicle control to head and scalp on day 1.